Background The aim of this study was to assess the long-term usage patterns and safety of
infliximab in patients with Crohn's disease in clinical practice. Methods The medical records …

AB s T r ACT infliximab is an accepted induction and maintenance treatment for patients with
Crohn's disease. The effectiveness of infliximab has been demonstrated for both active …

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract
characterized by recurring flares followed by periods of inactive disease and remission. The …

Background and aims: This study evaluates the long-term safety of infliximab in patients with
inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The …

Very recently infliximab--a tumour necrosis factor blocking antibody--was registered as an
important novel immunomodulating therapy for active Crohn's disease in the Netherlands …

Increasing evidence that tumor necrosis factor-α (TNF-α) plays a key role in orchestrating
inflammatory responses in a wide range of immune-mediated diseases has led to the …

The 5-year anniversary of the commercial release of infliximab for the treatment of moderate
to severe and fistulous Crohn's disease (CD) has been characterized by the publication of …

Infliximab was first introduced in Europe in 1999 for Crohn's disease. During the following
decade major progress was made in the understanding of the pathophysiology of …

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and
pharmacoeconomic impact of infliximab in the treatment of Crohn's disease (CD) and …

Background Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor
necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the …